Monday, Progenics Pharmaceuticals Inc. (PGNX) reported a first-quarter net loss that narrowed from the year-ago period primarily due to higher revenues and lower expenses.
The Tarrytown, New York-based company reported a first-quarter net loss of $1.79 million or $0.06 per share narrrower than a net loss of $15.49 million or $0.52 per share in the corresponding quarter last year. On average, six analysts polled by Thomson Reuters estimated a net loss of $0.29 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues for the quarter increased to $20.90 million from $14.76 million in the corresponding period last year. Analysts estimated revenues of $15.70 million for the quarter.
Total expenses for the quarter was $23.48 million compared to $32.21 million in the corresponding period last year.
Research and development expenses for the first-quarter of fiscal 2009 declined to $14.83 million from $22.79 million in the comparable period of fiscal 2008.
The company had a royalty expense of $18,000 compared to none in the first-quarter of fiscal 2008.
Depreciation and amortization charge for the quarter was $1.20 million compared to $1.11 million in the prior-year's quarter.
Operating loss for the quarter narrowed to $2.58 million from $17.44 million in the same period last year.
Progenics Pharmaceuticals closed Monday's regular trading at $5.66, up $0.24 or 4.43%, on a volume of 290,509 shares on the Nasdaq. In after-hour trading, the stock gained 74 cents or 13.07% and is trading at $6.40.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.